Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

D2C7-IT and Atezolizumab for the Treatment of Recurrent Glioblastoma

Trial Status: closed to accrual

This phase I trial studies the side effects of D2C7-immunotoxin (IT) when given together with atezolizumab in treating patients with glioblastoma that has come back (recurrent). An immunotoxin is a human-made protein that consists of a targeting portion linked to a toxin. The toxin is based on a portion of a common bacteria that the immune system cells will recognize. D2C7-IT is engineered to recognize two receptors, epidermal growth factor wild type (EGFRwt) and epidermal growth factor variant type III (EGFR-vIII). These receptors are expressed in many glioblastoma cells. Atezolizumab is a monoclonal antibody that unblocks “checkpoint” proteins that interfere with the immune system attacking tumor cells. Combining D2C7-IT with a checkpoint inhibitor, such as atezolizumab, may be effective against glioblastoma.